Northwest Biotherapeutics (NWBO) EBITDA Margin (2010 - 2026)
Northwest Biotherapeutics' (NWBO) quarterly EBITDA Margin came in at 2206.48% in Q1 2026, up 240979.0% year-on-year from N/an in Q1 2025, and down 9.8% quarter-over-quarter from 2009.52% in Q4 2025.
Northwest Biotherapeutics (NWBO) EBITDA Margin (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' EBITDA Margin history runs 17 years deep, the most recent figure standing at 2206.48% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 240979.0% year-over-year to 2206.48% in Q1 2026; TTM through Mar 2026 was 3574.01%, a 104751.0% increase from a year earlier, with the FY2025 full-year figure at 4347.9%, up 46455.0% from the prior year.
- EBITDA Margin fell to 2206.48% in Q1 2026 per NWBO's latest filing, from 2009.52% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1473.18% in Q1 2023 and bottomed at 11281.68% in Q2 2025.
- The 5-year median for EBITDA Margin is 4145.94% (2024), against an average of 4795.89%.
- Biggest YoY gain for EBITDA Margin was 599870 bps in 2025; the steepest drop was 785737 bps in 2025.
- Year by year, EBITDA Margin stood at 3044.89% in 2022, then declined by 12 bps to 3402.7% in 2023, then sank by 135 bps to 8008.23% in 2024, then soared by 75 bps to 2009.52% in 2025, then fell by 10 bps to 2206.48% in 2026.
- Per Business Quant, the three latest NWBO EBITDA Margin figures stand at 2206.48% (Q1 2026), 2009.52% (Q4 2025), and 7160.0% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - | - |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn | 31.68% |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 23.02% |
| 10 | Northwest Biotherapeutics | 277.35 Mn | 275.56 Mn | - | -2,206.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,206.48% |
| Dec 31, 2025 | -2,009.52% |
| Sep 30, 2025 | -7,160.00% |
| Jun 30, 2025 | -11,281.68% |
| Mar 31, 2025 | -4,616.27% |
| Dec 31, 2024 | -8,008.23% |
| Sep 30, 2024 | -4,145.94% |
| Jun 30, 2024 | -3,424.31% |
| Mar 31, 2024 | -5,543.66% |
| Dec 31, 2023 | -3,402.70% |
| Sep 30, 2023 | -3,405.17% |
| Jun 30, 2023 | -6,754.73% |
| Mar 31, 2023 | -1,473.18% |
| Dec 31, 2022 | -3,044.89% |
| Sep 30, 2022 | -7,581.55% |
| Jun 30, 2022 | -4,423.27% |
| Mar 31, 2022 | -3,048.64% |
| Sep 30, 2021 | -2,871.14% |
| Jun 30, 2021 | -2,982.45% |
| Mar 31, 2021 | -8,188.28% |